Methenamine Hippurate
NDC Package 0115-1754-01

11-digit billing NDC: 00115175401

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Methenamine Hippurate is tablets, USP are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. Marketed by Amneal Pharmaceuticals Of New York Llc, this product is identified by NDC 0115-1754 and is authorized under FDA application ANDA076411.

Identification & Billing

NDC Package Code
0115-1754-01
Package Description
100 TABLET in 1 BOTTLE, PLASTIC
Product Code
11-Digit Billing Format
00115175401
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Methenamine Hippurate
Dosage Form
-
Usage Information
Methenamine hippurate tablets, USP are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. This drug should only be used after eradication of the infection by other appropriate antimicrobial agents.To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets, USP and other antibacterial drugs, methenamine hippurate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Regulatory & Marketing

Labeler Name
Amneal Pharmaceuticals Of New York Llc
FDA Application #
ANDA076411
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-01-2003
Listing Expiration
12-31-2022
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0115-1754-01 identifies a specific commercial package of 100 tablet in 1 bottle, plastic of Methenamine Hippurate, labeled by Amneal Pharmaceuticals Of New York Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Amneal Pharmaceuticals Of New York Llc on July 01, 2003. The current certification is valid through December 31, 2022.

How is this Amneal Pharmaceuticals Of New York Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00115175401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0115-1754-01
11-Digit CMS (5-4-2)
00115-1754-01

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.